Trial Profile
A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Durvalumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 17 Jul 2023 Planned End Date changed from 19 Jun 2023 to 19 Dec 2023.
- 19 Apr 2023 Planned End Date changed from 19 Dec 2022 to 19 Jun 2023.